Onasemnogene Abeparvovec-xioi
Pre-clinicalActive 1 views this week 0 watching💤 Quiet
Interest: 30/100
30
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Spinal Muscular Atrophy 1
Conditions
Spinal Muscular Atrophy 1
Trial Timeline
Sep 21, 2017 → Dec 2, 2030
NCT ID
NCT03421977About Onasemnogene Abeparvovec-xioi
Onasemnogene Abeparvovec-xioi is a pre-clinical stage product being developed by Novartis for Spinal Muscular Atrophy 1. The current trial status is active. This product is registered under clinical trial identifier NCT03421977. Target conditions include Spinal Muscular Atrophy 1.
What happened to similar drugs?
7 of 20 similar drugs in Spinal Muscular Atrophy 1 were approved
Approved (7) Terminated (1) Active (12)
Hype Score Breakdown
Clinical
3
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04042025 | Phase 3 | Active |
| NCT03837184 | Phase 3 | Completed |
| NCT03461289 | Phase 3 | Completed |
| NCT03505099 | Phase 3 | Completed |
| NCT03381729 | Phase 1 | Terminated |
| NCT03306277 | Phase 3 | Completed |
| NCT03421977 | Pre-clinical | Active |
Competing Products
20 competing products in Spinal Muscular Atrophy 1
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| SUN13837 injection + Placebo | Daiichi Sankyo | Phase 2 | 35 |
| Placebo + Reldesemtiv 150 mg + Reldesemtiv 450 mg | Astellas Pharma | Phase 2 | 35 |
| Allogeneic Human Induced Pluripotent Stem Cell (iPSC)-Derived Motor Neuron Progenitor Cells | Sun Pharmaceutical | Phase 2 | 42 |
| Allogeneic Human Induced Pluripotent Stem Cell (iPSC)-Derived Motor Neuron Progenitor Cells | Sun Pharmaceutical | Phase 1 | 36 |
| Elezanumab | AbbVie | Pre-clinical | 30 |
| Elezanumab + Placebo | AbbVie | Phase 2 | 35 |
| Ropivacaine + Bupivacaine | AstraZeneca | Phase 3 | 40 |
| Onasemnogene Abeparvovec-xioi | Novartis | Phase 1 | 21 |
| Zolgensma | Novartis | Pre-clinical | 33 |
| BVS857 + Placebo | Novartis | Phase 2 | 35 |
| AVXS-101 | Novartis | Phase 1 | 29 |
| Onasemnogene Abeparvovec-xioi | Novartis | Phase 3 | 44 |
| Onasemnogene Abeparvovec-brve | Novartis | Approved | 50 |
| Onasemnogene Abeparvovec-xioi | Novartis | Phase 3 | 40 |
| branaplam | Novartis | Phase 1/2 | 32 |
| Onasemnogene Abeparvovec-xioi | Novartis | Phase 3 | 40 |
| onasemnogene abeparvovec | Novartis | Phase 3 | 47 |
| onasemnogene abeparvovec-xioi | Novartis | Phase 3 | 40 |
| Risdiplam | Roche | Phase 1 | 29 |
| ATI355 | Novartis | Phase 1 | 29 |